Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation ...

Background Atrial fibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both ...

On Sunday morning, the Norwegian Royal House announced that Queen Sonja of Norway regained a normal heart rhythm and was discharged from Lillehammer Hospital, where she was under observation for ...

The primary effectiveness endpoint – defined as freedom from AF, atrial flutter, atrial tachycardia ... analysis of 1,600 patients with atrial fibrillation who underwent a device implantation ...

Is your heart flutter just anxiety, or is it something deeper? And what exactly is atrial fibrillation anyway? To answer those questions, CNHI News Indiana reached out to Dr. Anil Ranginani ...

One study found most—but not all—patients with chronic lymphocytic leukemia disease progression while taking a Bruton ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

The following is a summary of “Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD ...

AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...